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Abstract 
 
Descriptive epidemiology has traditionally only been concerned with the definition of 
a research problem’s scope. However, the greater availability and improvement of 
epidemiological data over the years has led to the development of new statistical 
techniques that have characterized modern epidemiology. These methods are not only 
explanatory, but also predictive. In public health, predictions of future morbidity and 
mortality trends are essential to evaluate strategies for disease prevention and 
management, and to plan the allocation of resources. 
During my PhD at the school of “Epidemiology, Environment and Public Health” I 
worked on the analysis of cancer mortality trends, using data from the World Health 
Organization (WHO) database, available on electronic support (WHOSIS), and from 
other databases, including the Pan American Health Organization database, the 
Eurostat database, the United Nation Population Division database, the United States 
Census Bureau and the Japanese National Institute of Population database. 
Considering several cancer sites and several countries worldwide, I computed age-
specific rates for each 5-year age-group (from 0–4 to 80+ or 85+ years) and calendar 
year or quinquennium. I then computed age-standardized mortality rates per 100,000 
person-years using the direct method on the basis of the world standard population. I 
performed joinpoint models in order to identify the years when significant changes in 
trends occurred and I calculated the corresponding annual percent changes. 
Moreover, I focused on projections. I fitted joinpoint models to the numbers of certified 
deaths in each 5-year age-group in order to identify the most recent trend slope. Then, 
I applied Generalized Liner Model (GLM) Poisson regressions, considering different 
link functions, to the data over the time period identified by the joinpoint model. In 
particular, I considered the identity link, the logarithmic link, the power five link and 
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the square root link. I also implemented an algorithm that generated a “hybrid” 
regression; this algorithm automatically selects the best fitting GLM Poisson model, 
among the identity, logarithmic, power five, and square root link functions, to apply 
for each age-group according to Akaike Information Criterion (AIC) values. The 
resulting regression is a combination of the considered models. 
Thus, I computed the predicted age-specific numbers of deaths and rates, and the 
corresponding 95% prediction intervals (PIs) using the regression coefficients 
obtained previously from the four GLM Poisson regressions and from the hybrid GLM 
Poisson regression. Lastly, as a further comparison model, I implemented an average 
model, which just computes a mean of the estimates produced by the different 
considered GLM Poisson models. 
In order to compare the six different prediction methods, I used data from 21 countries 
worldwide and for the European Union as a whole, I considered 25 major causes of 
death. I selected countries with over 5 million inhabitants and with good quality data 
(i.e. with at least 90% of coverage). I analysed data for the period between 1980 and 
2011 and, in particular, I considered data from 1980 to 2001 as a training dataset, and 
from 2002 to 2011 as a validation set. To measure the predictive accuracy of the 
different models, I computed the average absolute relative deviations (AARDs). These 
indicate the average percent deviation from the true value. I calculated AARDs on 5-
year prediction period (i.e. 2002-2006), as well as for 10-year period (i.e. 2002-2011). 
The results showed that the hybrid model did not give always the best predictions, and 
when it was the best, the corresponding AARD estimates were not very far from the 
other methods. However, the hybrid model projections, for any combination of cancer 
site and sex, were never the worst. It acted as a compromise between the four 
considered models. The average model is also ranked in an intermediate position: it 
never was the best predictive method, but its AARDs were competitive compared to the 
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other methods considered. Overall, the method that shows the best predictive 
performance is the Poisson GLM with an identity link function. Furthermore, this 
method, showed extremely low AARDs compared to other methods, particularly when 
I considered a 10-year projection period. 
Finally, we must take into account that predicted trends and corresponding AARDs 
derived from 5-year projections are much more accurate than those done over a 10-
year period. Projections beyond five years with these methods lack reliability and 
become of limited use in public health. 
 
During the implementation of the algorithm and the analyses, several questions 
emerged: Are there other relevant models that can be added to the algorithm? How 
much does the Joinpoint regression influence projections? How to find an “a priori” 
rule that helps in choosing which predictive method apply according to various 
available covariates? All these questions are set aside for the future developments of 
the project. 
Prediction of future trends is a complex procedure, the resulting estimates should be 
taken with caution and considered only as general indications for epidemiology and 
health planning. 
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Introduction 
 
Descriptive epidemiology and its statistical techniques are fundamental instruments 
for exploratory studies in order to generate new hypotheses and/or verify them. 
Descriptive epidemiology is usually considered a first approach to define the purpose 
and scope of a research investigation. 
The basic techniques of descriptive epidemiology were borrowed from demography 
and the key descriptive tools were morbidity and mortality rates. Their comparison and 
their standardization were and are still the main methods used; however, statistical 
variability was rarely taken into account, sometimes producing serious errors and 
misleading interpretations 1. 
Over the years, especially cancer registries have improved the quantity and the quality 
of data, also working on the standardization of definitions/classifications and on 
registration procedures. Cancer incidence and mortality data are routinely recorded in 
cancer registries, and became the basic data for cancer surveillance. On the other hand, 
demographic data were also published on a more regular basis and became available 
for an increasing number of populations 2. 
The improvement and the greater availability of epidemiological and time based 
mortality data over the years brought the development of techniques that characterized 
modern descriptive epidemiology. These new techniques, mainly based on 
mathematical modelling, were developed focusing on the analysis of time series. They 
aimed to identify different factors that underlie the changes in rates. Specifically, 
historical oncologic data recorded in cancer registries could provide us with rich 
information on the changes of cancer incidence and mortality over the years; the trends 
of changing rates reflect the changes of the underlying risks. Thus, the collection of 
increasingly detailed morbidity and mortality data, and the creation of data systems 
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which allow cases and deaths to be located in time and space, have provided a solid 
basis for the evaluation of time series trends, in turn requiring the development of 
appropriate statistical methods. These methods are not only explanatory, but also 
predictive 1. 
Prediction of a future event is a complex process subject to large uncertainties and, for 
many aspects, questionable. However, in several human activities and working areas, 
it is useful to obtain information on future trends, even if uncertain or imprecise. In 
demography, for example, it is common practice to produce population structure 
projections for future decades, although it is known that the fertility, mortality and 
migratory patterns may vary considerably in relatively short periods, and thus 
substantially modify the subsequent population structure. Regarding oncologic data, 
which are at the basis of this thesis, the prediction of future cancer mortality rates is 
essential to plan the allocation of resources and to evaluate strategies for prevention 
and cancer management. Indeed, the actual available data are, usually, 2-3 or more 
years old 3. 
During my PhD studies in the school of “Epidemiology, Environment and Public 
Health” I worked on the analysis of cancer mortality trends; my focus was on 
projections. Over the first year of my PhD I implemented a predictive method that I 
continued to investigate and improve during the second and third years. I started 
developing an algorithm to compute a “hybrid” regression, that was a mixture of linear, 
log-linear, power five, and square root regressions. This algorithm automatically chose 
the best model to apply for predictions according to R-squared values. I compared the 
hybrid regression results to those from linear and log-linear regressions. Then, during 
my second year, I replaced the simple linear regressions with more appropriate 
models: I considered Poisson Generalized Linear Model (GLM) regressions with 
different link functions (identity, logarithmic, power five and square root) and refined 
 9 
 
the algorithm that automatically, now on the basis of Akaike information criterion 
(AIC) values instead of R-squared ones, selected the best fitting model to use, 
generating the hybrid regression. 
All these models have been applied to the European Union (EU) data, including several 
cancer sites. Data referred to the period 1980-2011; I used data from 1980 to 2001 as 
a training dataset so that I could “predict” data for the following period 2002-2011 
(validating dataset). Then, I compared the predicted data with the observed with the 
aim to identify the most performing model. 
A further step that I have achieved during my third year of PhD was to extend the 
database to other 21 countries besides the EU, and to other several causes of death, for 
a total of 25, obtaining a more consistent database and, as a consequence, estimates. 
Then, in addition to reviewing the algorithm, I also added an average model, which just 
computes a mean of the estimates produced by the different considered GLM Poisson 
models. 
Thus in this thesis, I will describe the methods and modelling techniques I used to 
study and project mortality rates in detail. I will also describe the main results obtained 
by applying the six different models previously described: the GLM Poisson models 
with the identity, logarithmic, power five, and square root link functions, the hybrid 
regression and the average regression.  
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Mortality rate 
 
Introduction 
 
In epidemiology, there are several indicators and measures to describe different 
aspects of a population’s health. The rate is the most widely used. It measures the 
instantaneous change of a quantity (for example the switch from health to sickness or 
from living to dead) compared to the change in unit of another quantity (time). 
If the event of interest is the number of deaths occurring in a population for a given 
cause in a certain period, the most suitable indicator is the mortality rate. 
 
Instantaneous risk 
 
To identify factors that cause an event (for example the disease onset or the death of 
an individual) it is necessary to calculate its risk, i.e. the probability of that event, which 
will depend on either individual characteristics, such as age, or environmental factors. 
The risk function determines how the risk of an event’s occurrence changes over time 
or with age. 
To give a definition of risk it is necessary to specify a time scale to measure it against 
an initial time point from which the risk will be measured. In epidemiology (as well as 
in demography), time can be measured in three ways: age, calendar period, and cohort 
of birth. The first two time indices correspond to the Lexis diagram axes 1. 
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Figure 1. Lexis diagram. 
 
Figure 1 illustrates the Lexis diagram structure. Every segment of oblique lines in this 
graph represent the observable fraction of an individual life, from the starting 
observation and the event realization (i.e. the interval of time and age during which an 
event of interest can occur). The left extremity of the segment represents the start of 
observation (for example the date of birth or the time of treatment initiation), the right 
one is the end of observation (the date and age at which either the event under study 
occurred or the subject stopped being observed). In order to obtain a measure of the 
time from initial observation since the occurrence of the event, you can project the 
oblique segment on one of the two axes of the diagram. 
 
Once a time scale is established, the distribution of the time between the starting 
observation and the occurrence of the event is of fundamental importance. If for 
example the interest is in studying the risk of dying after a cancer diagnosis, 
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distribution knowledge of the time elapsing between diagnosis and death, would allow 
to calculate the risk of death within a year of diagnosis, or the probability of surviving 
up to a given age. 
Thus, an appropriate mathematical model to calculate these risks is essential. The main 
assumption is that the event under study is a non-recurring event, i.e. once it has 
occurred, it cannot be repeated another time for the same individual. Death is 
obviously a non-recurring event, while the onset of a disease is not necessarily so. 
 
Consider the following quantities: 
 𝑻 - is a random variable representing the time before the occurrence of a specific 
event for a subject in a certain population. 𝑇 must be positive (𝑇 > 0), i.e. at the 
beginning of observation the individual must not have experienced the event. 
 𝒇(𝒕) - is the density function of 𝑇 and 𝑭(𝒕) = 𝑃(𝑇 ≤ 𝑡) is the probability 
distribution (𝐹′(𝑡) = 𝑓(𝑡)). 
 𝑺(𝒕) - is the survival function, that is the probability that a subject experiences 
the event over a certain time t. 𝑺(𝒕) = 𝑃(𝑇 > 𝑡) = 1 − 𝐹(𝑡). 
 
The instantaneous rate or risk function is defined as: 
 
𝜆(𝑡) = 𝑙𝑖𝑚
∆𝑡→0
1
∆𝑡
 𝑃𝑟(𝑡 ≤ 𝑇 < 𝑡 + ∆𝑡|𝑇 ≥ 𝑡) 
 
The previous formula is the ratio between the conditional probability that the event 
occurs at time 𝑡 and the corresponding time interval ∆𝑡 4.  
The instantaneous rate 𝜆(𝑡) is not a probability, but a probability per unit time, also 
called probability rate. 
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The event of interest, for mortality data analysis, is death and it is called the 
instantaneous mortality rate. The higher 𝜆(𝑡), more likely a death will occur between t 
and the next instant, therefore 𝜆(𝑡) provides a measure of the force of mortality at time 
𝑡. 
 
It is possible to rewrite 𝜆(𝑡) with the following formula: 
 
𝜆(𝑡) = 𝑙𝑖𝑚
∆𝑡→0
1
∆𝑡
𝐹(𝑡 + ∆𝑡) − 𝐹(𝑡)
1 − 𝐹(𝑡)
 
 
Which, replacing 1 − 𝐹(𝑡) with 𝑆(𝑡), becomes: 
 
𝜆(𝑡)𝑆(𝑡) = 𝑙𝑖𝑚
∆𝑡→0
𝐹(𝑡 + ∆𝑡) − 𝐹(𝑡)
∆𝑡
 
 
𝜆(𝑡)𝑆(𝑡) = 𝐹′(𝑡) 
 
Thus, the probability that an event occurs before a certain time t, 𝜋(𝑡), can be written 
as: 
 
𝜋(𝑡) = ∫ 𝐹′(𝑢)𝑑𝑢
𝑡
0
 
or also as: 
 
𝜋(𝑡) = ∫ 𝜆(𝑢)𝑆(𝑢)𝑑𝑢
𝑡
0
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The probability of death,  𝜋, between age 𝑡0 and 𝑡1, can be define as: 
 
𝜋 = ∫ 𝜆(𝑢)𝑆(𝑢)𝑑𝑢
𝑡1
𝑡0
 
 
Where 𝜆(𝑢) is the age-specific rate and 𝑆(𝑢) the probability of survival without disease 
1. 
 
The main interest focuses on the calculation of the conditional probability of death, 𝜋𝑐, 
between the age 𝑡0 and 𝑡1 given that a subject is still at risk at age 𝑡0. This probability is 
not influenced by overall survival until the age 𝑡0 and, if the range between 𝑡0 and 𝑡1 is 
small, influenced very little by survival. 
Then, it is possible to calculate 𝜋𝑐 using the following formula: 
 
𝜋𝑐 = ∫ 𝜆(𝑢)
𝑆(𝑢)
𝑆(𝑡0)
𝑡1
𝑡0
𝑑𝑢 
 
Under the assumption that the interval [𝑡0; 𝑡1] is small enough, 𝜆(𝑢) and 𝑆(𝑢) can be 
considered constant - 𝜆(𝑡0), 𝑆(𝑡0), then the equation can be rewritten in the following 
form: 
 
𝜋𝑐 ≈ 𝜆(𝑡0)(𝑡1 − 𝑡0) 
 
If 𝑒 is the number of observed events between 𝑡0 and 𝑡1, and 𝑛𝑡0  the number of subjects 
at risk at time 𝑡0, then the following formula gives the 𝜋𝑐 estimate: 
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𝜋?̂? =
𝑒
𝑛𝑡0
 
And the estimate for 𝜆 is: 
 
?̂?(𝑡0) ≈
𝑒
𝑛𝑡0(𝑡1 − 𝑡0)
 
 
Consequently, dividing the number of observed events by the number of person years 
(𝑚) accumulated between 𝑡0 and 𝑡1, you obtain the more familiar estimate formula of 
the instantaneous rate at time 𝑡0: 
 
?̂?(𝑡0) ≈
𝑒
𝑚
 
 
If 𝜆(𝑢) varies markedly between 𝑡0 and 𝑡1, or if the ratio 𝑆(𝑢) 𝑆(𝑡0)⁄  is very different 
from unity, this approximation does not hold 1. 
 
We can define the instantaneous rate as 4: 
 
𝜆 =  
𝑝
𝑡
 =  
𝑒
𝑛⁄
𝑡
 =  
𝑒
𝑛 ∗ 𝑡
 
 
That is: 
𝜆 =  
𝑒𝑣𝑒𝑛𝑡 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦
𝑜𝑏𝑠𝑒𝑟𝑣𝑎𝑡𝑖𝑜𝑛 𝑡𝑖𝑚𝑒
 =  
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓𝑒𝑣𝑒𝑛𝑡𝑠
𝑠𝑢𝑏𝑗𝑒𝑐𝑡𝑠 𝑎𝑡 𝑟𝑖𝑠𝑘⁄
𝑜𝑏𝑠𝑒𝑟𝑣𝑎𝑡𝑖𝑜𝑛 𝑡𝑖𝑚𝑒
 = 
 
       =  
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑒𝑣𝑒𝑛𝑡𝑠
𝑠𝑢𝑏𝑗𝑒𝑐𝑡𝑠 𝑎𝑡 𝑟𝑖𝑠𝑘 ∗ 𝑜𝑏𝑠𝑒𝑟𝑣𝑎𝑡𝑖𝑜𝑛 𝑡𝑖𝑚𝑒
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Thus, the rate is an instantaneous quantity because the observation time is only used 
as an operational element, to make the calculations (average rate). However, since the 
follow-up time appears directly in the rate definition, the rate takes into account the 
events that occurred and the time during which they occurred 4. 
 
Crude mortality rate 
 
The crude mortality rate measures the frequency of deaths observed in a population in 
a given period of time (conventionally a calendar year) and is the easiest to calculate. 
 
Formal definition of mortality rate: 
The ratio between the number of deaths from a certain cause that occurred in the study 
population in a given period (= numerator) and the total population at risk in the same 
period considered (= denominator). 
 
𝑀𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 𝑟𝑎𝑡𝑒 =  
 𝑛° 𝑜𝑓 𝑑𝑒𝑎𝑡ℎ𝑠 𝑓𝑟𝑜𝑚 𝑎 𝑐𝑒𝑟𝑡𝑎𝑖𝑛 𝑐𝑎𝑢𝑠𝑒 
𝑡ℎ𝑎𝑡 𝑜𝑐𝑐𝑢𝑟𝑟𝑒𝑑 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑡𝑢𝑑𝑦 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 
𝑖𝑛 𝑎 𝑔𝑖𝑣𝑒𝑛 𝑝𝑒𝑟𝑖𝑜𝑑
𝑡𝑜𝑡𝑎𝑙 𝑝𝑒𝑟𝑠𝑜𝑛 − 𝑡𝑖𝑚𝑒 𝑎𝑡 𝑟𝑖𝑠𝑘 
𝑖𝑛 𝑡ℎ𝑒 𝑠𝑎𝑚𝑒 𝑔𝑖𝑣𝑒𝑛 𝑝𝑒𝑟𝑖𝑜𝑑
 
 
The mortality rate indicates the average speed with which a group of individuals 
switches from a state of risk to a state of death in the time unit. 
 
In the specific case of annual mortality rates, the numerator of the rate is the number 
of deaths for the observed condition during the calendar year, while the denominator, 
consists of the population estimates derived from the census. In other words, the 
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person-years are expressed as the number of individuals present in mid-year (or the 
yearly average). 
𝐴𝑛𝑛𝑢𝑎𝑙 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 𝑟𝑎𝑡𝑒
=
 𝑛° 𝑜𝑓 𝑑𝑒𝑎𝑡ℎ𝑠 𝑓𝑟𝑜𝑚 𝑎 𝑐𝑒𝑟𝑡𝑎𝑖𝑛 𝑐𝑎𝑢𝑠𝑒 
𝑡ℎ𝑎𝑡 𝑜𝑐𝑐𝑢𝑟𝑟𝑒𝑑 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑡𝑢𝑑𝑦 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 
𝑑𝑢𝑟𝑖𝑛𝑔 𝑡ℎ𝑒 𝑐𝑎𝑙𝑒𝑛𝑑𝑎𝑟 𝑦𝑒𝑎𝑟
 
(𝑠𝑢𝑏𝑗𝑒𝑐𝑡𝑠 𝑎𝑡 𝑟𝑖𝑠𝑘 𝑎𝑡 𝑡ℎ𝑒 𝑏𝑒𝑔𝑖𝑛𝑛𝑖𝑛𝑔 + 𝑠𝑢𝑏𝑗𝑒𝑐𝑡𝑠 𝑎𝑡 𝑟𝑖𝑠𝑘 𝑎𝑡 𝑡ℎ𝑒 𝑒𝑛𝑑)
2
 
 
Since each population can be considered as a set of different homogeneous subgroups, 
the value of the generic rate can be seen as an average of the values measured in every 
subgroup.  
These values are weighted by the size of the specific subgroup: the larger the subgroup, 
the greater the influence on the crude measurement. 
 
Consider a population composed by age-subgroups, where: 
 𝑵 - is the total size of the population at risk; 
 𝑫 - is the total number of deaths observed in the population; 
 i - indicates i-th stratum; 
 𝒏𝒊 - is the size of the population in the i-th stratum; 
 𝒅𝒊 - is the number of deaths observed in the i-th stratum. 
 
The sum of all 𝑛𝑖 gives the total size of the population (𝑁), while the sum of all 𝑑𝑖 gives 
the total number of deaths (𝐷). The crude mortality rate is given by the ratio 𝐷 𝑁⁄ , that 
is the weighted average of the stratum specific mortality rates (
𝑑𝑖
𝑛𝑖⁄ ). Each specific 
mortality rate contributes with a weight proportional to its stratum population (
𝑛𝑖
𝑁⁄ ): 
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𝐷
𝑁
=  
∑ 𝑑𝑖
𝑛
𝑖=1
𝑁
=  
∑ 𝑛𝑖 (𝑑𝑖/𝑛𝑖)
𝑛
𝑖=1
𝑁
=  ∑ (
𝑛𝑖
𝑁
)
𝑛
𝑖=1
(
𝑑𝑖
𝑛𝑖
) =  ∑ 𝑤𝑖
𝑛
𝑖=1
(
𝑑𝑖
𝑛𝑖
) 
 
wi represent the weights and their sum is equal to unity: 
 
 ∑ 𝑤𝑖
𝑛
𝑖=1
= ∑ (
𝑛𝑖
𝑁
)
𝑛
𝑖=1
 =
∑ 𝑛𝑖 
𝑛
𝑖=1
𝑁
=
∑ 𝑛𝑖 
𝑛
𝑖=1
∑ 𝑛𝑖 
𝑛
𝑖=1
= 1 
 
Since mortality is strongly associated with age, age-specific mortality rates vary 
strongly with age. The crude rate does not account for this heterogeneity. This is a 
significant limit if the aim is to compare rates between different populations or 
between different periods: part of the observed differences could be due to this 
heterogeneity and variability between strata. 
The goal of the methods that will be presented in the next section is to obtain 
comparable measures between different populations. 
 
Standardized rates 
 
Since different intrinsic features characterize a population, the comparison of crude 
rates of different populations and different periods is inappropriate. In fact, each 
population differs from the other for socio-demographic, geographic, genetic, 
occupational, dietary, health and environmental aspects. There are significant 
differences regarding the distribution by age, sex, social class, occupation, etc. 
In order to compare mortality rates between different geographical regions, groups or 
calendar periods it is necessary to consider those factors in the calculation of the rates. 
It is essential to take into account variables which are already recognized as possible 
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explanations of observed differences in rates. Among these factors, age plays a key role 
and its effects are large. As mentioned in the previous paragraph, particularly for 
mortality rates, the age distribution of the individuals may change between the 
compared populations. If, for example, older age-groups are dominant in a population, 
the crude mortality rate will be higher compared to populations where there is a higher 
proportion of young people and children. This is simply because the risk of death in 
older people is greater than in the young 1, 5. 
Thus, “standardization” procedures are fundamental in order to make rates calculated 
on different populations comparable. Through standardization, it is possible to control 
certain known characteristics that can affect the value of the rates, obtaining estimates 
of weighted rates, based on a reference population, defined as a “standard population”. 
Since the occurrence of many health conditions is related to age, the most common 
standardization for data concerning public health is standardizing by age. 
There are two standardization techniques: direct standardization and indirect one. 
Below, the direct method is described 1, 6. 
 
Direct standardization 
 
This method aims to determine the annual rate that would be observed in a standard 
(or reference) population with a given age structure if it was subjected to the same 
mortality pressure of the studied population. 
This procedure calculates the expected number of cases (deaths) in each age-group of 
the standard population, applying the person-years of the standard population to the 
corresponding specific estimated rates of the studied population. Then, the total 
number of expected cases is divided by the total number of person-year in the reference 
population 1, 5. 
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The resulting rate indicates the frequency of an event if study population had the same 
age structure as the reference population. 
 
Consider: 
 𝒈 – the number of age-groups considered; 
 𝑳 – the size of standard population; 
 𝑳𝒊 – the size of the i-th age-group of the standard population; 
 𝒅𝒊 – the number of cases observed in the i-th age-group of the population 
under study; 
 𝒎𝒊 – the number of person-year accumulated in the i-th age-group of the 
population under study; 
 𝝀𝒊 =
𝑑𝑖
𝑚𝑖⁄  – the specific rate of the i-th age-group of the population under 
study. 
 
The following formula gives the standardized rate with the direct method: 
 
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑𝑖𝑧𝑒𝑑 𝑟𝑎𝑡𝑒 = 𝛬 =
1
𝐿
∑ 𝐿𝑖𝜆𝑖
𝑔
𝑖=1
 
 
𝐿𝑖𝜆𝑖 represents the number of expected cases that might be observed in one year in the 
i-th age-group of the standard population if it was exposed to a level of risk defined by 
the rate 𝜆𝑖. 
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Let: 
𝒘𝒊 – be the weight (proportion of subjects) of the i-th group of the standard 
population, equal to 𝐿𝑖/𝐿. 
The previous formula may be also written as: 
 
𝛬 = ∑ 𝑤𝑖𝜆𝑖
𝑔
𝑖=1
 
 
∑ 𝑤𝑖
𝑔
𝑖=1
= ∑ (
𝐿𝑖
𝐿
)
𝑔
𝑖=1
 =
∑ 𝐿𝑖 
𝑔
𝑖=1
𝐿
=
∑ 𝐿𝑖 
𝑔
𝑖=1
∑ 𝐿𝑖 
𝑔
𝑖=1
= 1 
 
The standardized rate 𝛬 is a weighted average of age-specific rates (𝜆𝑖); the weights are 
the proportion of individuals in the various age-groups of the standard population 5. 
Moreover, if two populations are characterized by the same age-specific rates, using 
the same standard population, the standardized rate will be the same regardless of 
their age structure. 
 
Reference populations are not necessary real populations, but can also be theoretical 
ones. 
The choice of the standard population depends on the study aim and influences the 
numerical results. When comparison among rates takes place in countries where age 
structures are similar to those of developed countries, the European population is 
suitable as a standard population, while the African population can be used as a 
reference for developing countries. It is also possible to restrict the standard 
population – truncated population – to certain age-groups, i.e. adult, when there is a 
specific interest. One of the most used reference populations is the world standard 
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population; the WHO provides it in order to make international comparisons easier. 
Its age structure and corresponding weights are reported below: 
 
Age - 
group 
Standard 
population 1960  
(* 100,000) 
Age - 
group 
Standard 
population 1960 
(* 100,000) 
0-4 12 45-49 6 
5-9 10 50-54 5 
10-14 9 55-59 4 
15-19 9 60-64 4 
20-24 8 65-69 3 
25-29 8 70-74 2 
30-34 6 75-79 1 
35-39 6 80-84 0.5 
40-44 6 85 + 0.5 
Total   100 
 
Table 1. World standard population age structure (1960 version) 7. 
 
Age - 
group 
Standard 
population 2001  
(* 100,000) 
Age - 
group 
Standard 
population 2001 
(* 100,000) 
0-4 8.86 45-49 6.04 
5-9 8.69 50-54 5.37 
10-14 8.60 55-59 4.55 
15-19 8.47 60-64 3.72 
20-24 8.22 65-69 2.96 
25-29 7.93 70-74 2.21 
30-34 7.61 75-79 1.52 
35-39 7.15 80-84 0.91 
40-44 6.59 85 + 0.63 
Total   100 
 
Table 2. World standard population age structure based on world average population between 2000-
2025 7. 
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Rate probability distribution and 
confidence intervals 
 
The age-specific rates, and consequently the standardized rates, are estimated from 
observations which are subject to a certain amount of random variability. This 
variability affects the estimate of the standardized rates and can bring to biased 
conclusions if the observed differences between standardized rates are mainly due to 
random variation. In order to evaluate the importance of this kind of variation the 
standardized rate 𝛬 should be presented with its standard error or its confidence 
interval 4, 8. 
The exact probability distribution for the rate is complicated due to the presence of 
censored data. For each unit 𝑖 observed over the time 𝑡𝑖, the events are distributed 
according to the Poisson probability distribution. Since events have a constant 
probability over time, the occurrence of an event does not influence the next one and 
the probability that two events occur at the same instant is zero. 
If this reasoning is extended to the whole study, you can assume to have many small 
Poisson processes. Assuming that all the experimental units are independent (as for 
mortality data), the study can be thought of as a set of independent Poisson processes: 
the result will be a Poisson distribution relative to the total number of events 4, 9. 
 
Let: 
 𝑫 – be the total number of deaths; 
 𝝀 – be the mortality rate; 
 𝒎 – be the total observed person time. 
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𝑝𝑟(𝑑 = 𝑥|𝐷) =
𝑒−𝐷 ∙ 𝐷𝑥
𝑥!
=
𝑒−𝜆𝑚(𝜆𝑚)𝑥
𝑥!
 
𝐸(𝐷) = 𝜆𝑚 
𝑉𝑎𝑟(𝐷) = 𝜆𝑚 
 
If 𝜆 is sufficiently small, and 𝐷 is much smaller than 𝑚, the Poisson distribution is a 
good approximation of the exact rate probability distribution. Moreover, the variability 
of the rate is considered to only be associated to its numerator (observed events), while 
the denominator (the population - time) is considered fixed and therefore not affected 
by random variability. Therefore, the accuracy of a rate only depends on the variability 
of the number of observed cases (𝐷) 1. 
When events are sufficiently numerous (≥20), the rate probability distribution is 
approximately Gaussian with mean: 
 
𝜇 =
𝐷
𝑚
 
 
and variance: 
 
𝜎2 =
𝐷
𝑚2
 
 
Thus, considering this approximation, the variance of the rate estimator ?̂? = 𝐷 𝑚⁄  is: 
 
𝑉𝑎𝑟(?̂?) = 𝑉𝑎𝑟 (
𝐷
𝑚
) =
𝑉𝑎𝑟(𝐷)
𝑚2
=
𝜆
𝑚
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Its estimate is obtained by replacing 𝜆 with 𝐷 𝑚⁄ : 
 
𝑉𝑎?̂?(?̂?) = 𝑉𝑎𝑟 (
𝐷
𝑚
) =
𝐷
𝑚2
=
?̂?2
𝐷
 
 
So, the variance of the specific rate ?̂?𝑖 is: 
 
𝑉𝑎𝑟(?̂?𝑖) =
𝑉𝑎𝑟(𝐷𝑖)
𝑚𝑖
2 =
𝜆𝑖
𝑚𝑖
 
 
For the standardized rate it is: 
 
𝑉𝑎𝑟(?̂?) = ∑ 𝑤𝑖
2𝑉𝑎𝑟(?̂?𝑖)
𝑔
𝑖=1
= ∑ 𝑤𝑖
2 (
𝜆𝑖
𝑚𝑖
)
𝑔
𝑖=1
 
 
𝜆𝑖 being unknown, this variance must be estimated by replacing 𝜆𝑖 by its estimate 
𝑑𝑖
𝑚𝑖⁄  
in the above expression 1. Then: 
 
𝑉𝑎?̂?(?̂?) = ∑ (
𝑤𝑖
2
𝑚𝑖
2) 𝑑𝑖
𝑔
𝑖=1
 
 
If the standardized rate is denoted by: 
 
µ = ?̂? = ∑ 𝑤𝑖𝜆𝑖
𝑖
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and if 𝑠 is the estimate of its standard error, then (?̂? − 𝜆𝑆𝐷) 𝑠⁄  approximates a standard 
normal variable. Therefore, it is possible to calculate the approximate confidence 
interval (IC) for µ: 
 
𝐼𝐶1−𝛼(𝛬) = [?̂? − 𝑧1−𝛼2
√𝑉𝑎?̂?(?̂?) , ?̂? + 𝑧
1−
𝛼
2
√𝑉𝑎?̂?(?̂?)] 
 
Where 1 − 𝛼 is the chosen confidence level and 𝑧1−𝛼
2
 is the quantile of level 1 −
𝛼
2
 of a 
standard normal distribution - 𝑁(0,1). 
For practical purposes rates are usually given as ?̂? per 100,000 person years (105 × ?̂?), 
consequently the variance needs to be presented as 1010 × 𝑉𝑎?̂?(?̂?).  
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Mortality trend analysis 
 
Estimated Annual Percent Change 
 
In order to describe mortality rate trends over time, it is useful to calculate the annual 
percent change (EAPC). 
The assumption is that the rates change constantly from year to year. Rates that change 
with a constant percentage every year change linearly on a logarithmic scale. For this 
reason, to estimate the EAPC of a series of data, the following regression model is used: 
 
log(𝜆𝑥) = 𝑏0 + 𝑏1𝑥 
 
Where log(𝜆𝑥) is the natural logarithm of the rate for the year 𝑥. 
 
The EAPC between the year 𝑥 and the year 𝑥 + 1 is equal to: 
 
𝐴𝑃𝐶𝑥,𝑥+1 = [
(𝜆𝑥+1 − 𝜆𝑥)
𝜆𝑥
] × 100 = [
(𝑒𝑏0+𝑏1(𝑥+1) − 𝑒𝑏0+𝑏1𝑥)
𝑒𝑏0+𝑏1𝑥
] × 100 = (𝑒𝑏1 − 1)  × 100 
 
However, it is unreasonable to describe the pattern of an entire data series in detail 
with a single EAPC, for this reason, it is useful apply a joinpoint regression model 10. 
This model, through statistical criteria, determines when and how often the EAPC 
changes significantly over the considered period 11. 
In mortality rates, the model is estimated through log-linear segments joined to each 
other. For example, rates can rise mildly for a certain period, have a strong upward 
trend during next years, to, then, decrease for the remaining time of the study. 
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Implementing the joinpoint model which best describes the data, is fundamental in 
order to determine how long the EAPC remains stable and when there is a change in 
trends. 
 
Joinpoint regression model 
 
The joinpoint regression model, proposed by Kim HJ et al 10, identifies the years 
characterized by a statistically significant change in mortality rates during the study 
period. This model is one of the most used and, moreover, is implemented by the 
Joinpoint software from the National Cancer Institute and freely available 12. 
Briefly, the joinpoint regression model assumes that the trend of the logarithm of the 
rate is linear. A linear segment can approximate a curve quite well, provided that it has 
the appropriate length. The joinpoint model identifies linear segments that fit the 
observed rates best, minimizing the sum of the squares of the distances between the 
points and the segments themselves 13. The points of statistically significant change in 
rates are called “joinpoints”. The number of segments that make up the trend can’t be 
more than the number of joinpoints arbitrarily set before the analysis. The year in 
which the joinpoint occurred is the year that identifies a change in trends. 
 
The software implements two different methods to obtain the model estimates: Grid 
Search and Hudson. The first method considers the observed values as discrete 
numbers and allows joinpoints to fall precisely on an observation. A better estimate 
can be obtained refining the grid, changing the program settings on the number of 
points to be placed between the X values observed in the grid (“Grid Search”) to a 
number greater than 0. In this way, the “Grid Search” method creates a grid of all 
possible positions in which the so-called joinpoints can fall, as specified in the settings, 
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and test the minimum sum of squared errors (SSE) for each model at k joinpoints, 
determining the best estimate. For low numbers of points between the observed values, 
this method is more efficient from a computational point of view. 
Hudson search considers the observed data as continuous and is more computationally 
intensive. 
The Joinpoint program also computes the EAPCs with the 95% confidence intervals 11. 
 
Statistical model 
 
The joinpoint regression for couple of observations (𝑥𝑖, 𝑦𝑖), for i= 1, ..., n, where 𝑦𝑖 
represents the observed mortality rates at the time 𝑥𝑖, can be written in the following 
way. 
 
Let: 
 k – be the number of unknown joinpoints; 
 𝝉𝒌 – be the k-th unknown joinpoint. 
 
𝐸[𝑦|𝑥] = 𝛽0 + 𝛽1𝑥 + 𝛿1(𝑥 − 𝜏1)
+ + ⋯ +  𝛿𝑘(𝑥 − 𝜏𝑘)
+ = 𝛽0 + 𝛽1𝑥 + ∑ 𝛿𝑖
𝑘
𝑖=1
(𝑥 − 𝜏𝑖)
+ 
 
(𝑥 − 𝜏𝑘)
+ = {
𝑥 − 𝜏𝑘    𝑝𝑒𝑟 𝑥 > 𝜏𝑘
0              𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒
 
 
In the literature, many authors studied this kind of non-linear model previously; it has 
been called in different ways, for example “piecewise regression”, “segmented 
regression”, “broken line regression” or “multi-phase regression” with a continuity 
constraint 14. 
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The parametrized log-linear model: 
 
𝑦 = 𝛽0 + 𝛽1𝑥 + 𝛿1(𝑥 − 𝜏1)
+ + ⋯ +  𝛿𝑘(𝑥 − 𝜏𝑘)
+ + 𝑒𝑟𝑟𝑜𝑟 
 
where 𝑦 = log (𝑟𝑎𝑡𝑒). 
 
In the case of a model without joinpoints the equation reduces to a simple linear model 
with intercept 𝛽0 and slope 𝛽1. While the terms 𝛿𝑖(𝑥 − 𝜏𝑖)
+ represent the change in 
slope for any subsequent segments and are equal to zero in the years prior to the 
joinpoints. 
 
For example, to determine up to 2 joinpoints, you must test a null hypothesis of no 
change with the alternative of 2 joinpoints. 
 
 𝐻0: 𝐸[𝑦|𝑥] = 𝛽0 + 𝛽1𝑥 
𝐻1: 𝑒𝑥𝑖𝑠𝑡 𝜏1 𝑎𝑛𝑑 𝜏2 (𝜏1 < 𝜏2) 𝑠𝑢𝑐ℎ 𝑡ℎ𝑎𝑡 𝐸[𝑦|𝑥] = 𝛽0 + 𝛽1𝑥 + 𝛿1(𝑥 − 𝜏1)
+ +  𝛿2(𝑥 − 𝜏2)
+ 
 
 If the null hypothesis is rejected, the same procedure is applied to a hypothesis 
test with 1 joinpoint versus 2 joinpoints; 
 
 If the null hypothesis is not rejected, it is tested against the 1 joinpoint 
alternative hypothesis. 
 
The best model is identified by a permutation test algorithm, which involves 
comparisons among models with different numbers of joinpoints. The first comparison 
is between the model without joinpoints and the model with a number of joinpoints 
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equal to the fixed maximum number. The final model is the model with the fewest 
parameters, for which the addition of a further parameter (joinpoint) does not lead to 
significant improvements. 
 
Once the best model is selected the EAPC estimate for each segment is: 
 
𝐴𝑃𝐶(𝜏𝑗,𝜏𝑗+1) = (𝑒
𝑏1+𝛿1+⋯+𝛿𝑗 − 1) × 100 
 
The Joinpoint program provides the EAPCs and the corresponding confidence 
intervals. 
 
Figure 2. Example of joinpoint output for lung cancer in men aged 40-44 years old. 
  
β1 
β2 = β1 + 𝛿1 
𝛕𝟐 
𝛕𝟏 
β3 = β1 + 𝛿1 + 𝛿2 
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Predictive analysis 
 
Introduction 
 
The prediction of future trends in incidence and mortality is essential to generate the 
epidemiological information necessary for resource allocation in health planning. 
This report focuses on cancer mortality rates. Cancer is a significant health issue with 
a huge burden on global population. Health specialists, planners and policy makers 
need information on the future cancer burden in order to prioritize prevention 
activities, allocate health services and resources, and evaluate the impact of 
interventions and treatments 3, 15. 
In general, for health planning, which is an integral part of cancer control programs, 
having information on future trends is a necessity. This is why projection methods are 
so important and accurate projections of future burden of cancer are essential. 
Statistical methods for cancer projections, which are commonly used when 
information on risk factors is not available, can be implemented in two steps: 
1) using historical data to model trends of cancer risk; 
2) extrapolating the trends into the future to project the numbers and rates. 
Statistical modelling of past trends allows to project cancer incidence and mortality 
trends by extrapolating time trends from observed rates. The number of new cancer 
cases or deaths is calculated by applying the estimated rates to projected population 
numbers. Projections based on the extrapolation of trends in cancer incidence and 
mortality over time assume that trends in risk behaviour will remain stable, no 
intervention or screening program will be started, and there is no change in diagnostic 
techniques. However, this assumption of unchanged trends in rates is very strong and 
may not be realistic 15. 
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Trends in cancer incidence or mortality may be described as trends over age at 
diagnosis or at death, year of diagnosis or death (period), and/or year of birth (cohort). 
Age is the most important time scale that affects cancer risk; it characterizes the 
cumulative exposure of the body to carcinogens over time. Period effects correspond 
to events that change incidence risk regardless of the age-group and are usually due to 
an environmental change. Cohort effects involve risk factors that a specific generation 
shared 3, 16. The trend of observed rates reflects the unobserved trend in cancer risk. 
Usually, the trend can be classified as (overall or age-specific) period trend and/or 
cohort trend, which lead to two classes of models: age-period models and age-period-
cohort models. In general, the period effects can modify the risk of cancer in both the 
short- (usually less than 5 years ahead) and the long-term (around 25 years ahead), 
cohort effects on the risk of cancer are more important for a long period than for a short 
period. So in general, the short-term projections are based on age-period models, while 
the long-term projections take cohort effects into account and are based on age-cohort 
or age-period-cohort models. 
Mathematically, trends can be described as linear or non-linear, and different 
statistical modelling techniques including parametric, semi-parametric and non-
parametric models can be used. Because different statistical methods can result in 
different cancer projections, it may be difficult to determine which method is more 
appropriate. Thus, appropriate statistical modelling is fundamental to obtain valid 
cancer projections 15. 
The literature proposes many statistical models for cancer projections, each focusing 
on different issues and aspects. Among these, short-term techniques include Poisson 
regression methods, those based on ARIMA models (Autoregressive Integrated 
Moving Average) for time series and Joinpoints. The most used long-term predictions 
methods rely on age-period-cohort models such as Nordpred 15, 17-21. 
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The following sections will present different models/projection methods, all based on 
an age-period model with joinpoints, that are used in an applicative scenario. 
 
Joinpoint regression on the number of 
deaths 
 
The trend analyses performed with joinpoint regression models can be used to predict 
mortality trends. 
This prediction method proceeds as follows: a joinpoint regression model is fit to the 
logarithm of the number of age-specific deaths for each 5-year age-group to identify 
the most recent trend segments (a). Subsequently, a regression model is applied to the 
mortality data for each age-group over the period identified by the last segment of the 
joinpoint model, in order to estimate the regression coefficients (b). This model is then 
used to predict mortality for future years, to calculate the number of expected age-
specific deaths and the corresponding 95% prediction intervals (IPs), that is, the 
confidence intervals for the prediction of each future value. These are calculated with 
a standard error that takes the variability of the new observation into account (c) 22, 23. 
Age-standardized mortality rates, with corresponding 95% PIs, are calculated using the 
number of expected age-specific deaths and the projected population data for the 
period of interest (d). 
 
During the statistical analysis for the paper titled “European cancer mortality 
predictions for the year 2016 with focus on leukaemia”, the authors noted that, for the 
0-14 years age-group , the model that best fit the leukaemia data was logarithmic, while 
for the other age-groups (all ages, 15-44, 45-69) the linear one worked well. Also for 
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these situations, I decided to implement an algorithm that would combine the four 
aforementioned models and select the best for each specific age-group automatically. 
In order to obtain projections of mortality data, I considered GLM Poisson regression 
models with four different link functions: the identity, logarithmic, power five and 
square root link. Furthermore, I implemented an algorithm that blends the above 
regression models, creating a new “hybrid” regression. This method calculates the 
number of expected age-specific deaths for each of the previous models; then for each 
age-group, sex and cancer site, the algorithm chooses the model with the best fit, based 
on the Akaike information criterion (AIC) statistic values. Thus, the algorithm chooses 
the best fitting model for each cause of death, sex and age-group, so the resulting total 
number of deaths and age-standardized rate could be calculated with different 
underlying link functions. The idea is that this hybrid model, automatically selects the 
best fitting model for each age-group, hopefully producing more accurate predictive 
estimates than the others. 
AIC statistic was chosen to compare the different model performances. Another useful 
statistic to compare models is the Bayesian information criterion (BIC). 
In addition to the previous models, I also considered a further simple model for 
projections: after obtaining the predicted estimates from the four GLM Poisson 
models, I computed the corresponding mean estimates, generating the average model. 
 
The following section describes the main characteristics of the Generalized Linear 
Models, considering different distributions and link functions. GLM Poisson 
regressions with identity, logarithmic, power five and square root link functions were 
used for projections, in the algorithm and in order to obtain the average model, 
assuming that the number of deaths over the last segment identified by the joinpoint 
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model followed this distribution and hence were projected according to this class of 
models. 
 
Exponential Family of Distribution and Generalized 
Linear Models 
 
Introduction 
The generalized linear model (GLM), as defined by Nelder and Wedderburn 24, could 
be considered as an extension of the classic linear regression model. GLMs aim to 
expand the classic linear regression to response variables (Y) which have distributions 
other than the Normal distribution. Since a non-Gaussian distribution is considered, 
the variance of Y is a function of its mean, thus the hypothesis of homoscedasticity at 
the basis of the linear regression collapses. 
The Bernoulli, Binomial, Poisson and the Negative Binomial are typical examples of 
random variables on which GLMs perform well. The common characteristic of all 
previous random variables is that the dependent variable distribution belongs to a 
wider class of distributions called Exponential Family of Distributions (EF). This class 
of distributions shares many properties from the Normal distribution. 
 
Exponential Family of Distribution 
A single random variable Y has a probability function, if it is discrete, or a probability 
density function, if continuous, and belongs to the exponential family (EF) if follows 
the form: 
 
𝑓(𝑦;  Ѳ, 𝜙) = 𝑒𝑥𝑝 {
𝑦Ѳ − 𝑏(Ѳ)
𝑎(𝜙)
+ 𝑐(𝑦, 𝜙)} 
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Where: 
- Ѳ is the canonical or natural parameter (Ѳ ∈ 𝛩 ⊆ ℝ); 
- 𝜙 is the dispersion parameter (𝜙 ∈ Ф ⊆ ℝ⁺); 
- 𝑎(•), 𝑏(•), 𝑐(•) are specific functions that identify a specific distribution function 
belonging to EF. 𝑎(•) depends only on the parameter 𝜙; 𝑏(•) depends only on 
Ѳ;  𝑐(•) depends on 𝑦 and 𝜙. Usually, 𝑎(𝜙) is defined as 
𝜙
𝜔⁄ , where 𝜔 is a known 
constant (𝜔 > 0). 
If 𝜙 is known, the 𝑓(𝑦;  Ѳ, 𝜙) is called canonical of natural form of the exponential 
family. 
 
Since 𝑏(Ѳ) is twice differentiable in Ѳ, its first derivative is an invertible function of Ѳ, 
and since 𝛩 is a convex set, the expected value of Y is: 
𝐸(𝑌) = 𝜇 =
𝑑𝑏(Ѳ)
𝑑Ѳ
= 𝑏′(Ѳ) 
 
And the variance of Y is:  
 
𝑉𝑎𝑟(𝑌) =
𝑑2𝑏(Ѳ)
𝑑Ѳ2
𝑎(𝜙) = 𝑏′′(Ѳ)𝑎(𝜙) =
𝑑𝜇
𝑑Ѳ
𝑎(𝜙) = 𝑉(𝜇)𝑎(𝜙) 
 
where the quantity: 
𝑑𝜇
𝑑Ѳ
= 𝑉(𝜇) 
 
is called variance function and it expresses the dependence between the variance and 
the mean of Y. In particular, if 𝑎(𝜙) = 1 the variance overlaps the variance function. 
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Moreover, under the same regularity conditions considered for 𝑏(Ѳ), the following 
relation is true: 
 
𝑑Ѳ
𝑑𝜇
=
1
𝑉(𝜇)
 
 
Many well-known distributions belong to the exponential family. For example, 
considering the probability function of a Bernoulli random variable: 
 
𝑓(𝑦;  𝜋) =  𝜋𝑦(1 −  𝜋)1−𝑦 = (1 − 𝜋) (
𝜋
1 − 𝜋
)
𝑦
 
 
Where 𝜋 represents the success probability. 
Applying the transformation: 
 
𝑓(𝑦;  𝜋) = 𝑒𝑥𝑝{ln (𝑓(𝑦;  𝜋)} 
 
We obtain: 
 
𝑓(𝑦;  𝜋) =  𝑒𝑥𝑝 {𝑙𝑛 [(1 − 𝜋) (
𝜋
1 − 𝜋
)
𝑦
]} = 𝑒𝑥𝑝 {𝑦 𝑙𝑛 (
𝜋
1 − 𝜋
) + ln (1 − 𝜋)} 
 
In this case the correspondence between parameters is: 
Ѳ = Ѳ(𝜋) =  𝑙𝑛 (
𝜋
1−𝜋
)  with Ѳ ∈ (−𝑖𝑛𝑓, +𝑖𝑛𝑓) 
𝑎(𝜙) = 𝜙 = 1   
𝑏(Ѳ) = 𝑙𝑛(1 + 𝑒Ѳ)  
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𝑐(𝑦, 𝜙) = 1  
 
The expected value is: 
 
𝐸(𝑌) = 𝜇 =
𝑑𝑏(Ѳ)
𝑑Ѳ
=
𝑑
𝑑Ѳ
[ln (1 + 𝑒Ѳ)] =
𝑒Ѳ
1 + 𝑒Ѳ
 
 
The variance (equal to the variance function) is: 
 
𝑉𝑎𝑟(𝑌) = 𝑉(𝜇) =
𝑑𝜇
𝑑Ѳ
=
𝑑
𝑑Ѳ
[
𝑒Ѳ
1 + 𝑒Ѳ
] = 𝜋(1 − 𝜋) 
 
Similarly, for the Binomial random variable: 
 
𝑓(𝑦; 𝑛, 𝜋) = (
𝑛
𝑦) 𝜋
𝑦(1 −  𝜋)𝑛−𝑦 
𝑦 = 0,1,2, … , 𝑛   and   0 < 𝜋 < 1 
 
Where n is the number of independent sets. 
 
The correspondence among parameters is: 
Ѳ = Ѳ(𝜋) =  𝑙𝑛 (
𝜋
1−𝜋
)  con Ѳ ∈ (−𝑖𝑛𝑓, +𝑖𝑛𝑓) 
𝑎(𝜙) = 𝜙 = 1   
𝑏(Ѳ) = 𝑛 𝑙𝑛(1 + 𝑒Ѳ)  
𝑐(𝑦, 𝜙) = ln (
𝑛
𝑦)  
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The expected value is: 
 
𝐸(𝑌) = 𝜇 =
𝑑𝑏(Ѳ)
𝑑Ѳ
=
𝑑
𝑑Ѳ
[𝑛 ln (1 + 𝑒Ѳ)] = 𝑛
𝑒Ѳ
1 + 𝑒Ѳ
= 𝑛𝜋 
 
The variance (equal to the variance function) is: 
 
𝑉𝑎𝑟(𝑌) = 𝑉(𝜇) =
𝑑𝜇
𝑑Ѳ
=
𝑑
𝑑Ѳ
[𝑛
𝑒Ѳ
1 + 𝑒Ѳ
] = 𝑛𝜋(1 − 𝜋) 
 
Considering the Poisson random variable: 
 
𝑓(𝑦; 𝜆) =
𝜆𝑦𝑒−𝜆
𝑦!
 
𝜆 > 0 
Applying the transformation: 
 
𝑓(𝑦;  𝜆) = 𝑒𝑥𝑝{ln (𝑓(𝑦;  𝜆)} = 𝑒𝑥𝑝{𝑦 𝑙𝑛𝜆 − 𝜆 − 𝑙𝑛(𝑦!)} 
We obtained the following correspondence: 
Ѳ = Ѳ(𝜆) =  𝑙𝑛 𝜆  with Ѳ ∈ (−𝑖𝑛𝑓, +𝑖𝑛𝑓) 
𝑎(𝜙) = 𝜙 = 1   
𝑏(Ѳ) = 𝑒Ѳ  
𝑐(𝑦, 𝜙) = −ln (y!)  
 
The expected value is: 
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𝐸(𝑌) = 𝜇 =
𝑑𝑏(Ѳ)
𝑑Ѳ
=
𝑑
𝑑Ѳ
[𝑒Ѳ] = 𝑒Ѳ = 𝜆 
 
The variance (equal to the variance function) is: 
 
𝑉𝑎𝑟(𝑌) = 𝑉(𝜇) =
𝑑𝜇
𝑑Ѳ
=
𝑑
𝑑Ѳ
[𝑒Ѳ] = 𝑒Ѳ = 𝜆 
 
Generalized Linear Models 
Consider Y a dependent random variable belonging to the Exponential Family of 
Distributions. The GLM models are specified by three components: 
1) the random component, which regards the dependent variable and its 
distribution; 
2) the systematic component, which regards the linear predictor (η=𝑥𝑡𝛽) that is 
the set of covariates (qualitative, quantitative or both). Usually the maximum 
likelihood method is used for parameter estimation; 
3) the link function (g), which specifies the relation between the expected value of 
Y and the systematic component. More precisely, the link is the function of the 
E(Y) which, in the model, will be equal to the linear predictor. It establishes a 
relation between the random component and the systematic one: 
 
𝑔(𝜇) = 𝜂 = 𝑥𝑡𝛽 
 
The link function must be monotonous and differentiable, thus an inverse link function 
(𝑔−1) exists such that: 
 
𝜇 = 𝐸(𝑌) = 𝑔−1(𝜂) = 𝑔−1(𝑥𝑡𝛽) 
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The link function choice and the Y distribution choice are independent. Given a specific 
Y distribution and a set of covariates, it is possible to define different link functions, 
and consequently different GLMs. 
However, some matches between the link function and the distribution of Y have 
particular properties. One of the most frequent link choice is the canonical link (Ѳ =
𝜂), which connect the canonical parameter and the linear predictor linearly: 
 
𝑔(𝜇) = Ѳ(𝜇) = Ѳ = 𝜂 = 𝑥𝑡𝛽 
 
In the previous formula, the canonical parameter depends from the mean 𝜇 and: 
 
𝜇 = 𝐸(𝑌) = Ѳ−1(𝜂) = Ѳ−1(𝑥𝑡𝛽) 
 
The identity link (𝜇 = 𝜂 = 𝑥𝑡𝛽) is a particular link function that specifies a linear 
model. 
 
In the case of a dependent variable with a Poisson distribution (𝑌 ∼ 𝑃𝑜𝑖(𝜆)), the 
canonical parameter is: 
 
Ѳ = Ѳ(𝜆) = ln (𝜆) 
and 𝜆 = 𝐸(𝑌) =  𝜇 
 
Then, the GLM model using the canonical link is the following: 
 
𝑔(𝜆) =  Ѳ(𝜆) = ln 𝜆 = 𝜂 = 𝑥𝑡𝛽 
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The previous is called log-linear Poisson model and it is usually used for count data 
response variables. 
 
Another possible link function is the probit link: 
 
𝜂 = ф−1[𝐸(𝑌)] 
 
where ф is the standardized Normal distribution function. 
 
In addition to the identity and logarithmic link, for the present report I also considered 
the power five link: 
𝑔(𝜇) = Ѳ(𝜇) = Ѳ1/5 = 𝜂 = 𝑥𝑡𝛽 
and the square root link: 
𝑔(𝜇) = Ѳ(𝜇) = Ѳ2 = 𝜂 = 𝑥𝑡𝛽 
 
The link function results in a linear transformation on the population averages and not 
on the values of the dependent variable. Unlike methods of transformation, the link 
function takes advantage from the source distribution of the response variable, 
allowing the results to be expressed in the source scale. 
It is crucial to identify the link function that can better interpret the response variable 
and its relation to the set of explanatory variables. Indeed, if the GLM model is not 
correctly specified, the results distribution and any inference drawn from them are not 
valid. 
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Comparison tests 
 
To measure the accuracy of the predicted figures and to compare the performance of 
the different projection methods, the prediction error is estimated by computing the 
predicted minus the observed values in absolute terms for every projected year. Then 
the ratio between the prediction error and the observed count is calculated (when the 
observed count is zero, it is necessary to add 0.5 to the denominator to avoid numerical 
errors). The ratio is the percentage error of the prediction, compared to the observed 
count 25, 26: 
 
𝑒𝑟𝑟𝑜𝑟 𝑟𝑎𝑡𝑖𝑜 =
|𝑒𝑠𝑡𝑖𝑚𝑎𝑡𝑒𝑑 𝑐𝑜𝑢𝑛𝑡 − 𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑐𝑜𝑢𝑛𝑡|
𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑐𝑜𝑢𝑛𝑡 (+0.5 when denominator is 0)
 
 
Finally, the average absolute relative deviation (AARD) is computed as the average of 
these error ratios: 
𝐴𝐴𝑅𝐷 =
1
𝑁
∑
|𝑒𝑠𝑡𝑖𝑚𝑎𝑡𝑒𝑑 𝑐𝑜𝑢𝑛𝑡𝑖 − 𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑐𝑜𝑢𝑛𝑡𝑖|
𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑐𝑜𝑢𝑛𝑡𝑖 + 0.5
𝑁
𝑖=1
 
 
where i =1 … N indicates a specific scenario. 
 
The AARD indicates the average percent deviation from the true value (number of 
observed deaths) relative to the true value. This measure attempts to take the relative 
differences in observed mortality counts and assess the extent to which the estimates 
deviate from the observed. 
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Smaller values of AARD indicate the predicted estimates are close to the observed 
value. In general a prediction is considered reliable when the AARD value is less than 
5% 18. 
Similar considerations of the number of deaths apply to rates. 
 
In particular in this thesis AARDs are computed for the six projection methods 
considered (Poisson GLM model with identity, logarithmic, power five and square root 
link, the hybrid regression and the average one); more specifically for each 
combination among cause of death, sex and projection methods, and also for categories 
of the mortality counts, from the rarest causes of deaths to the most common 25, 26.  
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Application to real data 
 
In this section the previously described projection methods are applied to real 
mortality data. 
 
Data and methods 
 
I obtained official cancer death certification data from 1980 to 2011 from the World 
Health Organization (WHO) database, available on electronic support (WHOSIS) 27. 
Figures were derived for 22 countries worldwide, including the European Union (EU) 
as a whole (28 countries as defined in July 2013, minus Cyprus due to data 
unavailability), and for 25 major causes of death (23 cancer sites and 2 cardiovascular 
diseases). I only selected countries with over 5 million inhabitants and with data 
coverage above 90% 28. 
Mortality data was coded according to the ICD - International Classification of 
Diseases, developed by the WHO. During the calendar period considered, three 
different Revisions of the International Classification of Diseases were used, the eighth 
(ICD-8), the ninth (ICD-9) and the tenth revision (ICD-10) 29, 30, 31. Since coding 
differences between various revisions were generally minor, all cancer deaths were 
recoded according to the tenth Revision of the ICD. 
From the WHO database, I obtained estimates of the resident population for the 
corresponding calendar periods, based on official censuses. When population data 
were missing for some European countries, they were derived from Eurostat 32. For the 
USA I retrieved population estimates from the Pan American Health Organization 
database (PAHO) 33. 
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I split the data: I used observed data from 1980 to 2001 as a training dataset, to which 
I applied the projection methods in order to predict data for the 2002-2011 period, and 
I used observed data from 2002 to 2011 as a validation dataset, to compare the different 
methods results. 
From the matrices of certified deaths and resident population, I computed age-specific 
observed rates for each 5-year age-group (from 0–4 to 80+ or 85+ years) and calendar 
year or quinquennium. I then computed age-standardized mortality rates per 100,000 
using the direct method on the basis of the world standard population. For the 
calculation of the EU rates, if data was missing for one or more calendar years within 
a country, I performed extrapolations using the nearest available data. 
Projections were derived by fitting a joinpoint model to the number of certified deaths 
in each 5-year age-group in order to identify the most recent trend period. 
Subsequently, Poisson GLM regressions with identity, logarithmic, power five and 
square root link functions and the hybrid regression (a combination of the previous 
four models), were applied to the mortality data in each age-group over the time period 
identified by the joinpoint model. I thus computed the predicted age-specific number 
of deaths, and the 95% prediction intervals (PIs) using the previously obtained 
regression coefficients and simulated standard error. Predicted standardized mortality 
rates, and their 95% PIs, were computed using the 2002-2011 populations. In this 
specific case, I applied the joinpoint regression model to the certified numbers of 
deaths over the 1980-2001 period, with the following constraints: 
 the number of available years following the last estimated joinpoint must be at 
least equal to 5; 
 the number of years between two subsequent joinpoints must be at least equal 
to 4; 
 the maximum number of joinpoints, decided before the analysis, is 5. 
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These constraints were set in order to consider more stable periods; however, it is 
possible that if there were significant changes in slope in more recent periods, the 
joinpoint couldn’t detect them. The last constraint, in particular, was set because I was 
working on the number of deaths, which has more fluctuation than rates. 
After obtaining predicted rates and the PIs for the models under study, I computed the 
average model, obtaining the corresponding average estimates. 
I then compared the performance of the different projection methods using the AARD 
score. 
 
The datasets submitted to the Joinpoint program were created with SAS 9.4 software, 
while for the projections, including the implementation of the hybrid model algorithm, 
I used R 3.2.3 software. 
 
Hybrid model 
 
In this paragraph, I explain the inner workings of the predictive algorithm. 
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Figure 3. A piece of the R program - “modPlog” function for the Poisson GLM logarithmic link 
function. 
 
In R, I constructed a function for each of the four Poisson GLM regressions considered. 
This function requires as arguments: a dataset containing the population estimates, 
the certified deaths, the age-standardized observed rates by cause of death, sex, year, 
age-group (Figure 4) and a dataset only containing the years for the predictions. 
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Figure 4. Example of dataset required in the Poisson GLM function (EU data). 
 
I used the “glm” function in R with a Poisson family, with the corresponding link 
functions. 
 
Then, I constructed a loop that, for each combination of cause of death, sex and age, 
submits the four GLM Poisson functions and compares the AIC values (Figure 5). 
 
 
Figure 5. A piece of the R program, the algorithm for predictions. 
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On the basis of the AIC values, the program choses which of the previous models to 
apply to each specific time series defined by cause of death, sex and age (i.e. 5 year age-
group) variable combinations. For each combination, I obtained parameter estimates 
with their accuracy measures (Figure 6). 
 
 
Figure 6. Dataset obtained after running the algorithm. 
 
Moreover, in the resulting dataset there is “model”, a variable that indicates which 
model, among the four considered, fits the data better in a specific cause of death, sex, 
and age-group combination. The previous figures show that for the predicted year 
2002, for the cause of death 1 (corresponding to the “Oral cavity and Pharynx” cause), 
for men aged 0-4 years the logarithmic link function model fit better according to the 
AIC statistic. Instead, in the 5-9 age-group, in the same cause of death and sex, the 
square root link function regression had a lower AIC. 
This new dataset was used to calculate the rates with their accuracy measures; in the 
end, we sum the projections by cancer site, and sex over all the age-groups. 
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The procedure for the Poisson GLM regressions with the four different link functions 
is similar, with the difference that each combination of age, cause of death, and sex, 
had the same model. 
I repeated the whole process for every country, sex and cause of death considered. 
 
Predictive analysis results 
 
Below, I will show and comment the most significant results obtained from the 
comparison of the six different projection methods (other specific comparisons are 
available in the supplementary material). Firstly, I compare results from specific 
cancer site and country in order to make the comprehension of more general tables 
easier. Then, I will analyse the more general results in detail, without country 
distinction. 
 
When I considered specific causes of death and specific countries, the resulting best 
prediction models are different. In order to make comparisons, I selected results from 
lung cancer, one of the major cause of deaths, for the EU, the USA and Japan. 
Moreover, I distinguished between 10-years projection (Table 3a) and 5-years 
projection, i.e. up to 2006 (Table 3b). From these specific tables, 5-years prediction are 
more precise and produced lower AARDs. Nevertheless, AARDs from 10- years 
projection are, most of the times, lower or around 5%, indicating good predicted 
estimates. 
 
 
 
 
 53 
 
Table 3a. AARDs on rate by projection method, and sex in the EU, in the USA and in Japan 
(projections up to 2011). 
 
AARD 
Men Women 
Hybrid Identity Log Average Power5 
Square 
Root Hybrid Identity Log Average Power5 
Square 
Root 
EU 0.00320 0.01113 0.01241 0.00305 0.00725 0.00276 0.04161 0.07846 0.03301 0.05394 0.04485 0.05944 
USA 0.05465 0.06605 0.05091 0.05721 0.05373 0.05814 0.05024 0.05492 0.04007 0.04394 0.04129 0.04514 
Japan 0.02231 0.05043 0.03335 0.01575 0.01810 0.01773 0.06243 0.02182 0.10163 0.06360 0.08147 0.05447 
 
Table 3b. AARDs on rate by projection method, and sex in the EU, in the USA and in Japan 
(projections up to 2006). 
 
AARD 
Men Women 
Hybrid Identity Log Average Power5 
Square 
Root Hybrid Identity Log Average Power5 
Square 
Root 
EU 0.00249 0.00339 0.00733 0.00326 0.00537 0.00281 0.02600 0.04384 0.02158 0.03147 0.02673 0.03371 
USA 0.06116 0.06649 0.05956 0.06246 0.06088 0.06290 0.06367 0.06578 0.05626 0.06042 0.05834 0.06128 
Japan 0.00853 0.03739 0.00800 0.01623 0.01001 0.01956 0.04575 0.02606 0.07281 0.05108 0.06239 0.04735 
 
The EU 
 
Considering the whole projection period, in the EU, the lowest AARD for men was that 
of square root link function model with an AARD (computed on rate) of 0.00276. 
However, also the hybrid and the average model worked very well (AARDs around 
0.003). At a graphical level (Figure 7a, d, f), observing these three models, it is possible 
notice that the continuous black line (the predicted trend) overlaps the points of the 
observed rates perfectly. Moreover, it seems that, in the final hybrid model, the square 
root and power five link functions are predominant. The square root and power five 
link figures (Figure 7e, f) in men are very similar to the hybrid one, even if the PIs, in 
particular for the square root, are slightly closer. Instead, the Poisson GLM identity 
and logarithmic link function model produced worse predictions with very similar 
AARD of about 0.012. 
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In EU women, over the 10-years period, the logarithmic link function predicted trend 
produced the lowest AARD, with a value of 0.03301. The predicted trend remained 
closer to the real one, but they did not overlap, however, the real trend is at least 
included in the PIs (Figure 7c). The hybrid model (AARD of 0.04161) was mainly 
influenced by the logarithmic link and by the power five link, this latter showed an 
AARD of 0.04485. Also in women, the identity link function produced the worst AARD 
(0.07846) and in Figure 7b it is possible to see that the predicted estimates 
underestimated the real trend. The square root link function model and the average 
model had AARDs of about 0.059 and 0.054 respectively, showing non-satisfactory 
predicted trends and PIs (Figure 7d, f). 
For this tumour and this country, the prediction intervals in men tended to contain the 
true rates, while in women the PIs are often at the limit. The AARDs for this cancer site 
are equal or lower than 5% (with the exception of identity link in women), thus the 
projections are quite good. Overall, in women the AARDs are higher than those of men. 
 
 
 
Hybrid regression 
 
Figure 7a. Projected lung cancer trends with the hybrid regression in men and women from the EU. 
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Poisson GLM – identity link 
 
Figure 7b. Projected lung cancer trends with the Poisson GLM identity link function in men and 
women from the EU. 
 
 
Poisson GLM – logarithmic link 
 
Figure 7c. Projected lung cancer trends with the Poisson GLM logarithmic link function in men and 
women from the EU. 
 
 
Average 
 
Figure 7d. Projected lung cancer trends with the Average model in men and women from the EU. 
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Poisson GLM – power five link 
 
Figure 7e. Projected lung cancer trends with the Poisson GLM power five link function in men and 
women from the EU. 
 
 
Poisson GLM – square root link 
 
Figure 7f. Projected lung cancer trends with the Poisson GLM square root link function in men and 
women from the EU. 
 
 
The USA 
 
In the USA, the 10-years predicted trends derived from Poisson GLM logarithmic link 
regression models are better than the other projection methods in both sexes, with 
AARDs of 0.05091 and 0.04007, in men and women respectively. In Figure 8c, it is 
possible to notice that the predicted estimates from this model followed the real rates 
quite well. 
The highest AARDs, in both sexes were for the identity link function model with values 
of 0.06605 in men and 0.05492 in women. 
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In men, the hybrid model, had an AARD value of about 0.055, very similar to the power 
five AARD and lower than the square root one (Figure 8a, e, f). 
In women, the hybrid regression was strongly influenced by the identity one, indeed 
the corresponding AARD is the second highest (0.05024). Instead AARDs for the 
average model, the power five and the square root are lower than 5%, the predicted 
trends are quite close to the real rate and the PIs are at the limits (Figure 8d, e, f). 
Overall, in women the AARDs are lower than in men. 
 
 
 
Hybrid regression 
 
Figure 8a. Projected lung cancer trends with the hybrid regression in men and women from the USA. 
 
 
Poisson GLM – identity link 
 
Figure 8b. Projected lung cancer trends with the Poisson GLM identity link function in men and 
women from the USA. 
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Poisson GLM – logarithmic link 
 
Figure 8c. Projected lung cancer trends with the Poisson GLM logarithmic link function in men and 
women from the USA. 
 
 
Average 
 
Figure 8d. Projected lung cancer trends with the Average model in men and women from the USA. 
 
 
Poisson GLM – power five link 
 
Figure 8e. Projected lung cancer trends with the Poisson GLM power five link function in men and 
women from the USA. 
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Poisson GLM – square root link 
 
Figure 8f. Projected lung cancer trends with the Poisson GLM square root link function in men and 
women from the USA. 
 
 
Japan 
 
In males from Japan, the best predictive method over the period 2002-2011 is the 
average model, with an AARD of 0.01575. The predicted trend overlaps the observed 
rates very well (Figure 9d); similarly, the Poisson GLM power five and square root link 
function regression methods work well with AARD values of around 0.018. The hybrid 
model was influenced negatively by the logarithmic link function, AARDs of 0.02231 
and 0.03335 respectively; the predicted trends from these models tended to 
overestimate the real data (Figure 9a, c), however, the data is within the PI limits. The 
identity link function regression produced the worst AARD, indeed the predicted trend 
substantially did not overlaps the real data, underestimating them (Figure 9b). 
In women, the more performant projection method is the Poisson GLM identity link 
function regression (AARD of 0.02182). As it is possible to see from Figure 9f, also the 
square root link function produced quite good predicted estimates (AARD of 0.05447). 
The hybrid model predicted slightly better than the average one with AARDs around 
0.06. The worst projections were from the logarithmic and power five link function; 
for these latter models the PIs did not include the real data (Figure 9c, e). 
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Hybrid regression 
 
Figure 9a. Projected lung cancer trends with the hybrid regression in men and women from Japan. 
 
 
Poisson GLM – identity link 
 
Figure 9b. Projected lung cancer trends with the Poisson GLM identity link function in men and 
women from Japan. 
 
 
Poisson GLM – logarithmic link 
 
Figure 9c. Projected lung cancer trends with the Poisson GLM logarithmic link function in men and 
women from Japan. 
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Average 
 
Figure 9d. Projected lung cancer trends with the Average model in men and women from Japan. 
 
 
Poisson GLM – power five link 
 
Figure 9e. Projected lung cancer trends with the Poisson GLM power five link function in men and 
women from Japan. 
 
 
Poisson GLM – square root link 
 
Figure 9f. Projected lung cancer trends with the Poisson GLM square root link function in men and 
women from Japan. 
 
In general, as can be seen in the various figures, the predicted estimates are more 
accurate when considering a 5-year period. The predicted line overlaps the observed 
rates more precisely and the PIs completely include the real trends more often.   
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Comprehensive analysis 
 
Considering the whole database (all countries, sex and causes of death), the AARD 
estimates are worse, probably due to the high data variability. Despite this, I obtained 
more consistent results than those for single country. Analysing the total AARDs 
computed on number of deaths over the entire period 2002-2011, the Poisson GLM 
regression with identity link function shows the lowest AARD value (0.16674), while 
the logarithmic link function has the highest AARD value (0.99326). The average 
regression has intermediate value (Table 4a). 
 
Table 4a. AARDs on number of deaths by projection method. 
AARD 
Hybrid Identity Log Average Power5 
Square 
Root 
0.92669 0.16674 0.99326 0.38447 0.21846 0.18069 
 
AARDs from 5-years projection are clearly lower (Table 4b), indicating definitely better 
predicted estimates. However, the best performance remains that from the identity 
link function method. The greater improvements passing from the AARDs computed 
on 10-years projection to those computer on 5-year projection are for the hybrid model 
and for the logarithmic link function method, that are also the worse ones. 
 
Table 4b. AARDs on number of deaths by projection method (projections up to 2006). 
AARD 
Hybrid Identity Log Average Power5 
Square 
Root 
0.15823 0.12932 0.17311 0.14416 0.14652 0.13479 
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Compared to the total AARDs computed on number of deaths, the ranking among 
AARDs computed on rates is the same, for both projections period (Table 5a and 5b). 
Over the whole period 2002-2011, the Poisson GLM regression with identity link 
function shows the lowest AARD value (0.22997), while the logarithmic link function 
has the highest AARD value (1.73099). 
 
Table 5a. AARDs on rate by projection method. 
AARD 
Hybrid Identity Log Average Power5 
Square 
Root 
1.64702 0.22997 1.73099 0.62624 0.30994 0.25376 
 
Also for 5-years projections, the identity link function method shows the best predicted 
estimates with an AARD value of 0.19064. The hybrid and the logarithmic AARDs 
strongly decrease considering a short projection period. 
 
Table 5b. AARDs on rate by projection method (projections up to 2006). 
AARD 
Hybrid Identity Log Average Power5 
Square 
Root 
0.23828 0.19064 0.25712 0.21487 0.21881 0.20229 
 
The following tables show the AARDs by projection method, sex and cause of death 
computed on numbers of deaths (Table 6) and on rates (Table 7) focusing on five-year 
projections; there is no by country distinction. In both tables and in both sexes, the 
identity link function most frequently presented lower AARDs as compared to the 
other link function models. For AARDs computed on numbers of deaths (Table 3), the 
square root link function model follows the identity link as the second best model for 
prediction for men, while in women the second best model was the hybrid. In men, the 
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power five model, and in women, the logarithmic and the average one were never the 
best model for any causes of deaths considered. Regarding AARDs calculated on rates 
(Table 7), in women, the logarithmic link function model, the average prediction 
method and the power five link were never the best. 
From these results it would seem that none of these methods are appropriate, since the 
best result shows AARDs over 10% for deaths and around 20% for rates. 
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Table 6. AARDs on number of deaths by projection method, sex and cause of death (projections up to 2006). 
 
AARD 
Men Women 
Hybrid Identity Log Average Power5 
Square 
root 
Hybrid Identity Log Average Power5 
Square 
root 
ORAL CAVITY, PHARYNX 0.07262 0.06155 0.08511 0.07212 0.07700 0.06896 0.15308 0.12232 0.16828 0.14393 0.15369 0.13823 
OESOPHAGUS 0.07133 0.07512 0.07368 0.06856 0.06930 0.06839 0.14795 0.12162 0.17686 0.15135 0.16165 0.14399 
STOMACH 0.07223 0.09342 0.06420 0.07319 0.06644 0.07415 0.06437 0.08217 0.06489 0.06540 0.06409 0.06612 
INTESTINE (COLON AND RECTUM) 0.03912 0.03621 0.04201 0.03710 0.03892 0.03608 0.05858 0.05600 0.07177 0.06216 0.06584 0.05994 
GALLBLADDER AND BILE DUCTS 0.14349 0.14056 0.15491 0.14180 0.14649 0.13904 0.13800 0.14606 0.15459 0.13229 0.13601 0.13183 
PANCREAS 0.05757 0.06728 0.05260 0.05599 0.05357 0.05754 0.05130 0.05142 0.06169 0.05115 0.05440 0.04986 
OTHER DIGESTIVE ORGANS 1.38842 0.81078 1.46002 1.06020 1.02685 0.90199 0.58909 0.49725 0.62150 0.54329 0.54489 0.52369 
LARYNX 0.10403 0.09904 0.12830 0.10965 0.11418 0.10387 0.49016 0.42971 0.51526 0.48485 0.49302 0.46360 
LUNG 0.03284 0.03474 0.03660 0.03365 0.03453 0.03328 0.04851 0.06969 0.05821 0.05508 0.05348 0.05695 
BONE & ARTICULAR CARTILAGE 0.22357 0.22299 0.23907 0.23094 0.23167 0.22588 0.31135 0.26414 0.34306 0.29235 0.29004 0.27036 
SKIN INCLUDING MELANOMA 0.13714 0.10573 0.15014 0.11730 0.12201 0.10840 0.08844 0.08431 0.09946 0.08890 0.09307 0.08659 
BREAST . . . . . . 0.04232 0.03512 0.05327 0.04143 0.04682 0.03945 
UTERUS (CERVIX AND CORPUS) . . . . . . 0.06198 0.06281 0.06685 0.06109 0.06320 0.06011 
PROSTATE 0.07282 0.06390 0.08249 0.07099 0.07503 0.06815 . . . . . . 
BLADDER 0.11233 0.07651 0.12230 0.08503 0.08071 0.07513 0.09444 0.09540 0.11690 0.10080 0.10583 0.09824 
KIDNEY AND OTHER URINARY SITES 0.12198 0.07792 0.13996 0.09885 0.09859 0.08532 0.11427 0.08205 0.12966 0.10121 0.10922 0.09327 
BRAIN AND NERVES, BENIGN OR MALIGNANT 0.07920 0.06313 0.08949 0.07049 0.07744 0.06570 0.08079 0.07778 0.09621 0.07630 0.08260 0.07345 
THYROID 0.27272 0.19900 0.28689 0.24014 0.24684 0.22153 0.21924 0.17783 0.23825 0.19805 0.20117 0.18736 
HODGKIN'S DISEASE 0.26370 0.28292 0.28640 0.26527 0.26317 0.25691 0.57478 0.36638 0.59919 0.44173 0.43186 0.38608 
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AARD 
Men Women 
Hybrid Identity Log Average Power5 
Square 
root 
Hybrid Identity Log Average Power5 
Square 
root 
MULTIPLE MYELOMA 0.12009 0.09531 0.18267 0.13341 0.14672 0.11850 0.13512 0.10900 0.16121 0.13423 0.14504 0.12763 
LEUKEMIAS 0.10111 0.07495 0.12112 0.09628 0.10630 0.08958 0.09162 0.06242 0.11609 0.08885 0.09939 0.08166 
ALL CANCERS (malignant and benign) 0.03104 0.02730 0.03364 0.02918 0.03102 0.02833 0.03674 0.02951 0.03894 0.03417 0.03642 0.03319 
ALL CAUSES 0.03035 0.03602 0.02864 0.03058 0.02922 0.03083 0.04413 0.04429 0.04628 0.04452 0.04530 0.04427 
CHD (CORONARY HEART DISEASES) 0.06321 0.07187 0.06490 0.06225 0.06306 0.06237 0.06278 0.06585 0.07141 0.06487 0.06771 0.06411 
CVD (CEREBROVASCULAR DISEASES) 0.09642 0.08349 0.10787 0.09579 0.10114 0.09304 0.07860 0.07900 0.08606 0.07999 0.08305 0.07941 
 
Table 7. AARDs on rate by projection method, sex and cause of death (projections up to 2006). 
 
AARD 
Men Women 
Hybrid Identity Log Average Power5 
Square 
root 
Hybrid Identity Log Average Power5 
Square 
root 
ORAL CAVITY, PHARYNX 0.08685 0.07052 0.10284 0.08615 0.09385 0.08256 0.21148 0.16990 0.23104 0.20067 0.21403 0.19373 
OESOPHAGUS 0.07450 0.07583 0.08200 0.07354 0.07622 0.07231 0.26010 0.21376 0.29004 0.25281 0.26807 0.24383 
STOMACH 0.06707 0.09041 0.06342 0.06963 0.06442 0.07043 0.06539 0.07187 0.07580 0.06785 0.07057 0.06743 
INTESTINE (COLON AND RECTUM) 0.04331 0.03643 0.04842 0.04195 0.04472 0.04052 0.06612 0.05889 0.07757 0.06740 0.07183 0.06533 
GALLBLADDER AND BILE DUCTS 0.18946 0.17490 0.21373 0.19332 0.20293 0.19074 0.19530 0.15859 0.22735 0.18158 0.19218 0.16922 
PANCREAS 0.05080 0.05955 0.05027 0.05058 0.04982 0.05149 0.06200 0.05672 0.06899 0.05851 0.06076 0.05678 
OTHER DIGESTIVE ORGANS 2.07846 1.36193 2.15328 1.64826 1.61948 1.46753 1.03143 0.82767 1.08501 0.93199 0.94094 0.88373 
LARYNX 0.15079 0.13833 0.17478 0.15283 0.16214 0.14828 1.01596 0.95679 1.04293 1.00179 1.01758 0.99147 
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AARD 
Men Women 
Hybrid Identity Log Average Power5 
Square 
root 
Hybrid Identity Log Average Power5 
Square 
root 
LUNG 0.03573 0.03904 0.03820 0.03692 0.03699 0.03680 0.05882 0.06312 0.07398 0.05756 0.05960 0.05490 
BONE & ARTICULAR CARTILAGE 0.26898 0.26509 0.28674 0.27286 0.27804 0.26981 0.50321 0.42584 0.56015 0.47836 0.48385 0.44901 
SKIN INCLUDING MELANOMA 0.15280 0.10337 0.17464 0.12906 0.13621 0.11638 0.12384 0.11533 0.13534 0.12470 0.12940 0.12292 
BREAST . . . . . . 0.04116 0.03911 0.04680 0.03961 0.04308 0.03921 
UTERUS (CERVIX AND CORPUS) . . . . . . 0.07315 0.06902 0.08053 0.07188 0.07498 0.07032 
PROSTATE 0.08702 0.07091 0.10015 0.08427 0.08951 0.08075 . . . . . . 
BLADDER 0.14718 0.07789 0.15881 0.09710 0.08867 0.07856 0.17785 0.15203 0.20240 0.17588 0.18513 0.16955 
KIDNEY AND OTHER URINARY SITES 0.13912 0.08243 0.15562 0.10635 0.10353 0.09019 0.14026 0.11729 0.15498 0.13486 0.14201 0.13032 
BRAIN AND NERVES, BENIGN OR MALIGNANT 0.08826 0.07132 0.09641 0.07992 0.08514 0.07607 0.10102 0.07960 0.10699 0.08796 0.09145 0.08243 
THYROID 0.49748 0.43418 0.51711 0.47629 0.48819 0.46597 0.51653 0.39189 0.54625 0.45269 0.45688 0.42257 
HODGKIN'S DISEASE 0.33115 0.33212 0.39608 0.34502 0.35679 0.33964 1.15592 0.65710 1.20671 0.84497 0.82199 0.71912 
MULTIPLE MYELOMA 0.16202 0.13072 0.21126 0.16728 0.18135 0.15479 0.21172 0.17681 0.23699 0.20895 0.22110 0.20267 
LEUKEMIAS 0.10453 0.07941 0.12279 0.09867 0.10895 0.09338 0.09370 0.08592 0.11023 0.09265 0.10039 0.08964 
ALL CANCERS (malignant and benign) 0.03313 0.03048 0.03546 0.03228 0.03367 0.03164 0.02785 0.02534 0.03086 0.02715 0.02878 0.02681 
ALL CAUSES 0.03630 0.04679 0.03503 0.03867 0.03608 0.03916 0.03780 0.04431 0.03899 0.03846 0.03815 0.03865 
CHD (CORONARY HEART DISEASES) 0.05349 0.06672 0.05634 0.05303 0.05395 0.05320 0.06354 0.07371 0.07697 0.06839 0.07190 0.06766 
CVD (CEREBROVASCULAR DISEASES) 0.09670 0.08037 0.10850 0.09460 0.10101 0.09176 0.07486 0.07353 0.08655 0.07730 0.08216 0.07682 
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Conclusions 
 
Cancer mortality trend analyses are important for public health, but current year and 
future rate trend predictions are essential in order to allocate resources and health 
services wisely and to prioritize specific prevention activities. 
This report aims to describe statistical techniques used in mortality trend analyses, 
both for descriptive (the EAPC) and inferential (the joinpoint model and the 
projection) studies. Moreover, it describes and compares projections obtained through 
six different models: Poisson GLM regressions with identity, logarithmic, square root, 
power five link functions, a “hybrid” model and an “average” model. The hybrid model 
is the results of an algorithm implemented in the R software that combines, in the final 
standardized rate, estimates from the four previous Poisson GLM model (identity, 
logarithmic, square root, power five link function regression models), choosing the 
more performing model for each age-group, sex, and cancer site according to the AIC 
statistic. The average model, simply computes a mean of the predicted estimates 
obtained from the same four models. 
 
The overall results show that, differently from what I expected, the hybrid model does 
not give the best predictions, and when it does, the corresponding AARD estimate is 
not very far from the AARDs of the other methods. However, the hybrid model 
projections, for any combination of cancer site and sex, are never the worst. Rather, it 
appears as a compromise of the four models considered, though heavily influenced by 
the logarithmic model. In the examples from this thesis, its predictive trend does not 
perfectly overlap the observed trend, but it is not very far off. The average model 
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predicted estimates are in general better than the hybrid ones, even if they were never 
the best. 
 
Overall, the AARDs from the six methods are quite similar, there was a strong 
difference only in a few cases. Moreover, it is possible to notice that, often, the hybrid 
regression shows AARDs closer to those of Poisson GLM logarithmic link function 
regression, compared to the other methods. Checking the data, I saw that the algorithm 
that generated the hybrid model, selected the logarithmic function more frequently as 
this function fits the data better more often. In any case, the Poisson GLM logarithmic 
link function method turns out to be a bad predictive function, in spite of fitting 
existing data better. 
Paradoxically, the method that shows the best predictive performance is the Poisson 
GLM with the identity link function. This method showed much lower AARDs 
compared to other methods, even when I considered a 10-years projection period. 
Annually, my research group produced projection estimates for major cancer site in 
Europe and worldwide using a simple identity model. The results from this thesis 
encourage continuing to produce predicted estimates through an identity method; 
furthermore my research group predicts only for very short periods. 
 
Some more general considerations. Projection methods which apply joinpoint 
regression models to the number of deaths, produce better predicted estimates on 
number of deaths compared to rates. Considering small countries and minor causes of 
deaths, i.e. low numbers, causes unreliable projections regardless of the methods used. 
Finally, we must take into account that predicted trends and corresponding AARDs 
estimates derived from 5-year projections are definitely better than those on long 
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periods. Projections over more than five years lack accuracy and, become less relevant 
to discussions. 
 
One of my aims, through the application to greater more varied data, was to be able to 
classify problems in order to select the most accurate predictive model according to 
geographic area, cause of death, sex, age structure and other available covariates. 
Instead, the results from specific analyses, single country and single cancer sites, are 
quite discordant. There is no model that emerges as the best in predictive 
performances. This suggest that there is still a lot to do in order to find an “a priori” or 
mechanic rule that helps in choosing which predictive method to apply according to 
various covariates. 
 
During the implementation of the algorithm and the analyses, several interesting 
angles for further analysis emerged. 
To compare and choose the best model for each age-group, sex, and cancer site, the 
algorithm uses the AIC statistic, but there may be better statistics for comparing the 
different models? 
We retrieved the four transformations used in the algorithm from the literature, are 
there other relevant and more performant models? 
How much does the Joinpoint program influence the projections? It would be 
interesting to use the Joinpoint program for all the data available through 2011 and 
then break the dataset to 2001. In this way, the last segment identified by the joinpoint 
could lead to different coefficient estimates. Furthermore, are the 5 years following the 
last estimated joinpoint too many? 
All these questions are set aside for future development of the project. 
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In conclusion, prediction of future trends is a complex procedure; hence the resulting 
estimates should always be taken with caution and considered only as a general 
indication for epidemiology and health planning.  
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Supplementary material 
 
Tables 
 
Table 1S. AARDs on rate by cancer site and projection method (projections up to 2006). 
 
AARD 
Hybrid Identity Log Average Power5 
Square 
Root 
ORAL CAVITY, PHARYNX 0.14916 0.12021 0.16694 0.14341 0.15394 0.13815 
OESOPHAGUS 0.16730 0.14480 0.18602 0.16318 0.17215 0.15807 
STOMACH 0.06623 0.08114 0.06961 0.06874 0.06749 0.06893 
INTESTINE (COLON AND RECTUM) 0.05472 0.04766 0.06299 0.05468 0.05827 0.05292 
GALLBLADDER AND BILE DUCTS 0.19238 0.16674 0.22054 0.18745 0.19755 0.17998 
PANCREAS 0.05640 0.05813 0.05963 0.05455 0.05529 0.05414 
OTHER DIGESTIVE ORGANS 1.55495 1.09480 1.61915 1.29012 1.28021 1.17563 
LARYNX 0.58337 0.54756 0.60885 0.57731 0.58986 0.56988 
LUNG 0.04728 0.05108 0.05609 0.04724 0.04830 0.04585 
BONE & ARTICULAR CARTILAGE 0.38609 0.34547 0.42344 0.37561 0.38094 0.35941 
SKIN INCLUDING MELANOMA 0.13832 0.10935 0.15499 0.12688 0.13280 0.11965 
BREAST 0.04116 0.03911 0.04680 0.03961 0.04308 0.03921 
UTERUS (CERVIX AND CORPUS) 0.07315 0.06902 0.08053 0.07188 0.07498 0.07032 
PROSTATE 0.08702 0.07091 0.10015 0.08427 0.08951 0.08075 
BLADDER 0.16251 0.11496 0.18061 0.13649 0.13690 0.12406 
KIDNEY AND OTHER URINARY SITES 0.13969 0.09986 0.15530 0.12060 0.12277 0.11026 
BRAIN AND NERVES, BENIGN OR MALIGNANT 0.09464 0.07546 0.10170 0.08394 0.08830 0.07925 
THYROID 0.50700 0.41303 0.53168 0.46449 0.47254 0.44427 
HODGKIN'S DISEASE 0.74354 0.49461 0.80139 0.59499 0.58939 0.52938 
MULTIPLE MYELOMA 0.18687 0.15376 0.22413 0.18812 0.20123 0.17873 
LEUKEMIAS 0.09911 0.08267 0.11651 0.09566 0.10467 0.09151 
ALL CANCERS (malignant and benign) 0.03049 0.02791 0.03316 0.02972 0.03122 0.02923 
ALL CAUSES 0.03705 0.04555 0.03701 0.03856 0.03712 0.03890 
CHD (CORONARY HEART DISEASES) 0.05852 0.07022 0.06665 0.06071 0.06292 0.06043 
CVD (CEREBROVASCULAR DISEASES) 0.08578 0.07695 0.09752 0.08595 0.09159 0.08429 
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Table 2S. AARDs on number of deaths by cancer site and projection method (projections up to 
2006). 
 
AARD 
Hybrid Identity Log Average Power5 
Square 
Root 
ORAL CAVITY, PHARYNX 0.11285 0.09193 0.12669 0.10803 0.11535 0.10359 
OESOPHAGUS 0.10964 0.09837 0.12527 0.10995 0.11548 0.10619 
STOMACH 0.06830 0.08779 0.06454 0.06929 0.06526 0.07014 
INTESTINE (COLON AND RECTUM) 0.04885 0.04611 0.05689 0.04963 0.05238 0.04801 
GALLBLADDER AND BILE DUCTS 0.14075 0.14331 0.15475 0.13705 0.14125 0.13543 
PANCREAS 0.05444 0.05935 0.05715 0.05357 0.05398 0.05370 
OTHER DIGESTIVE ORGANS 0.98876 0.65402 1.04076 0.80174 0.78587 0.71284 
LARYNX 0.29709 0.26437 0.32178 0.29725 0.30360 0.28373 
LUNG 0.04067 0.05221 0.04741 0.04437 0.04401 0.04512 
BONE & ARTICULAR CARTILAGE 0.26746 0.24357 0.29106 0.26165 0.26085 0.24812 
SKIN INCLUDING MELANOMA 0.11279 0.09502 0.12480 0.10310 0.10754 0.09750 
BREAST 0.04232 0.03512 0.05327 0.04143 0.04682 0.03945 
UTERUS (CERVIX AND CORPUS) 0.06198 0.06281 0.06685 0.06109 0.06320 0.06011 
PROSTATE 0.07282 0.06390 0.08249 0.07099 0.07503 0.06815 
BLADDER 0.10339 0.08595 0.11960 0.09291 0.09327 0.08669 
KIDNEY AND OTHER URINARY SITES 0.11812 0.07998 0.13481 0.10003 0.10390 0.08930 
BRAIN AND NERVES, BENIGN OR MALIGNANT 0.07999 0.07046 0.09285 0.07340 0.08002 0.06958 
THYROID 0.24598 0.18842 0.26257 0.21910 0.22401 0.20444 
HODGKIN'S DISEASE 0.41924 0.32465 0.44280 0.35350 0.34752 0.32149 
MULTIPLE MYELOMA 0.12760 0.10215 0.17194 0.13382 0.14588 0.12307 
LEUKEMIAS 0.09637 0.06869 0.11860 0.09256 0.10284 0.08562 
ALL CANCERS (malignant and benign) 0.03389 0.02840 0.03629 0.03168 0.03372 0.03076 
ALL CAUSES 0.03724 0.04016 0.03746 0.03755 0.03726 0.03755 
CHD (CORONARY HEART DISEASES) 0.06299 0.06886 0.06815 0.06356 0.06539 0.06324 
CVD (CEREBROVASCULAR DISEASES) 0.08751 0.08125 0.09696 0.08789 0.09209 0.08622 
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Table 3S. AARDs on rate by sex and projection method (projections up to 2006). 
 
AARD 
Hybrid Identity Log Average Power5 
Square 
Root 
Men 0.21457 0.16912 0.23211 0.19103 0.19375 0.17869 
Women 0.26100 0.21127 0.28110 0.23772 0.24284 0.22493 
 
 
Table 4S. AARDs on number of deaths by sex and projection method (projections up to 2006). 
 
AARD 
Hybrid Identity Log Average Power5 
Square 
Root 
Men 0.16006 0.12534 0.17409 0.14160 0.14253 0.13017 
Women 0.15647 0.13313 0.17217 0.14661 0.15035 0.13923 
 
 
Table 5S. AARDs on rate by categories of mortality counts and projection method (projections up to 
2006). 
 
AARD 
Hybrid Identity Log Average Power5 
Square 
Root 
≤50000 1.14924 0.79471 1.21027 0.94256 0.93480 0.85250 
50000-100000 0.44655 0.37925 0.47756 0.42005 0.42674 0.40184 
100000-500000 0.19836 0.17060 0.21839 0.19114 0.19930 0.18436 
>500000 0.06931 0.06469 0.07756 0.06676 0.06909 0.06458 
 
 
Table 6S. AARDs on number of deaths by categories of mortality counts and projection method 
(projections up to 2006). 
 
AARD 
Hybrid Identity Log Average Power5 
Square 
Root 
≤50000 0.70400 0.48933 0.74178 0.57762 0.56669 0.51717 
50000-100000 0.25672 0.21599 0.27682 0.24037 0.24243 0.22628 
100000-500000 0.13278 0.11481 0.15116 0.12848 0.13453 0.12206 
>500000 0.06285 0.06079 0.07005 0.06174 0.06372 0.06008 
 
